Patents by Inventor Nathan Trinklein

Nathan Trinklein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
    Publication number: 20260176366
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Application
    Filed: March 5, 2026
    Publication date: June 25, 2026
    Applicant: TENEOBIO, INC.
    Inventors: Nathan TRINKLEIN, Katherine Harris, Kyle Lorentsen, Harbani Kaur MALIK CHAUDHRY, Kaitlyn Loughlin
  • ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS
    Publication number: 20260159566
    Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: February 5, 2026
    Publication date: June 11, 2026
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, TeneoBio, Inc.
    Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
  • TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES
    Publication number: 20260090529
    Abstract: Human or chimeric heavy chain-only antibodies are provided, in the native amino acid residue at the first position of the fourth framework region (FR4) of said HCAb is substituted by a different amino acid residue that is capable of disrupting a surface-exposed hydrophobic patch comprising or associated with the native amino acid residue at that position.
    Type: Application
    Filed: November 18, 2025
    Publication date: April 2, 2026
    Inventors: Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, Mike Osborn
  • Agonistic anti-IL-2R antibodies and methods of use
    Patent number: 12590163
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: March 31, 2026
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • CD3 BINDING ANTIBODIES
    Publication number: 20260085115
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: June 2, 2025
    Publication date: March 26, 2026
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Anti-B-cell maturation antigen chimeric antigen receptors with human domains
    Patent number: 12570717
    Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: March 10, 2026
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, TeneoBio, Inc.
    Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
  • ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20260048122
    Abstract: Anti-CD19 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD19.
    Type: Application
    Filed: June 16, 2025
    Publication date: February 19, 2026
    Inventors: Nathan Trinklein, Katherine Harris, Brian Avanzino, Joseph S. Lucas, Laura Davison, Blair B. Madison, Karen Chang
  • Transgenic non-human animals producing modified heavy chain-only antibodies
    Patent number: 12495776
    Abstract: Human or chimeric heavy chain-only antibodies are provided, in the native amino acid residue at the first position of the fourth framework region (FR4) of said HCAb is substituted by a different amino acid residue that is capable of disrupting a surface-exposed hydrophobic patch comprising or associated with the native amino acid residue at that position.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: December 16, 2025
    Assignee: TeneoBio, Inc.
    Inventors: Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, Mike Osborn
  • ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20250346682
    Abstract: Anti-CD20 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD20.
    Type: Application
    Filed: June 12, 2025
    Publication date: November 13, 2025
    Inventors: Nathan Trinklein, Katherine Harris, Nicole Allen, Karen Chang, Brian Avanzino
  • CD3 BINDING ANTIBODIES
    Publication number: 20250340638
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: March 24, 2025
    Publication date: November 6, 2025
    Applicant: TENEOONE, INC.
    Inventors: Nathan TRINKLEIN, Wim VAN SCHOOTEN, Shelley FORCE ALDRED, Katherine HARRIS, Duy PHAM
  • ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES
    Publication number: 20250270337
    Abstract: Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: January 17, 2025
    Publication date: August 28, 2025
    Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
  • Anti-BCMA heavy chain-only antibodies
    Patent number: 12371505
    Abstract: Anti-BCMA heavy chain-only antibodies(HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: July 29, 2025
    Assignee: TeneoBio, Inc.
    Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
  • CD3-DELTA/EPSILON HETERODIMER SPECIFIC ANTIBODIES
    Publication number: 20250179180
    Abstract: Novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases are provided, as well as bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: January 27, 2025
    Publication date: June 5, 2025
    Inventors: Ute Schellenberger, Nathan Trinklein, Wim van Schooten
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
    Publication number: 20250066476
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: December 21, 2023
    Publication date: February 27, 2025
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • Heavy chain antibodies binding to CD19
    Patent number: 12202898
    Abstract: Anti-CD19 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD19.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: January 21, 2025
    Assignee: TeneoTwo, Inc.
    Inventors: Shelley Force Aldred, Wim van Schooten, Katherine Harris, Udaya Rangaswamy, Nathan Trinklein
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES BINDING TO CD22 AND CD3
    Publication number: 20240368274
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) binding to CD22 and CD3 are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of CD22.
    Type: Application
    Filed: January 4, 2024
    Publication date: November 7, 2024
    Inventors: Nathan Trinklein, Udaya Rangaswamy, Suhasini Iyer, Kirthana Prabhakar, Harshad Ugamraj
  • ANTI-PSMA ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240226162
    Abstract: Anti-PSMA antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of PSMA.
    Type: Application
    Filed: February 25, 2022
    Publication date: July 11, 2024
    Inventors: Starlynn Clarke, Brian Avanzino, Kevin Dang, Nathan Trinklein, Katherine Harris
  • ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240182597
    Abstract: Anti-MUC1-C antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of MUC1-C.
    Type: Application
    Filed: February 28, 2022
    Publication date: June 6, 2024
    Inventors: Katherine Harris, Brian Avanzino, Nathan Trinklein, Karen Chang, Nicole Allen
  • Anti-BCMA heavy chain-only antibodies
    Patent number: 11970540
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • ANTI-PSMA ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240131074
    Abstract: Anti-PSMA antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of PSMA.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Inventors: Starlynn Clarke, Brian Avanzino, Kevin Dang, Nathan Trinklein, Katherine Harris